Foghorn Therapeutics Inc (FHTX)
followers
·
Follow
Sector: | HEALTH CARE |
Industry: | PHARMACEUTICALS |
SIC: | PHARMACEUTICAL PREPARATIONS |
CEO: | Adrian Gottschalk |
Employees: | 120 |
Web site: | foghorntx.com |
500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA, 02139
617-586-3100
|
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|
Foghorn Therapeutics Inc. is developing a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome. The company is also developing an enzyme inhibitor and protein degrader as selective modulators of BRM.
Please log in first to see chart